文献速递肿瘤 PET/CT

基于纳米抗体的示踪剂[68Ga]Ga-NOTA-PFCM01在胰腺导管腺癌模型及非人灵长类中的c-Met免疫PET显像

ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-07-09

本研究开发了68Ga标记的纳米抗体[68Ga]Ga-NOTA-PFCM01用于胰腺导管腺癌(PDAC)模型c-Met显像。BXPC-3肿瘤2小时摄取为2.31±0.02%ID/g,离体分布为1.90±0.59%ID/g;在食蟹猴中经肾快速排泄,肝、胃、肠、胰腺和肌肉未见明显放射性摄取。

要点

  • TCGA和GTEx数据显示PAAD中MET表达显著高于正常组织(P < 0.001),高表达者总生存率较低。
  • PFCM01与c-Met结合KD值为0.16 nM,[68Ga]Ga-NOTA-PFCM01放化纯度高且体内外稳定性好。
  • BXPC-3肿瘤2小时摄取2.31±0.02%ID/g,离体分布1.90±0.59%ID/g,均高于对照。

主要发现

  • 基于TCGA和GTEx数据,胰腺腺癌(PAAD)中MET表达显著高于正常组织(P < 0.001),高MET表达患者总生存率低于低表达患者。
  • c-Met在BXPC-3细胞中表达最高、在MIA PaCa-2细胞中表达最低,分别设为阳性和阴性模型。
  • PFCM01被筛选出具有优异结合特性,KD值为0.16 nM。
  • [68Ga]Ga-NOTA-PFCM01放化纯度高,体内外稳定性好。
  • 小动物PET/CT半定量分析显示注射后2小时BXPC-3肿瘤摄取(2.31±0.02%ID/g)显著高于对照组,离体生物分布显示BXPC-3肿瘤摄取(1.90±0.59%ID/g)高于其他,组织学染色显示BXPC-3高表达c-Met而MIA PaCa-2低表达。

关键数值与推荐

  • TCGA和GTEx数据:PAAD中MET表达显著高于正常组织(P < 0.001)。
  • PFCM01与c-Met结合KD值为0.16 nM。
  • BXPC-3肿瘤注射后2小时摄取为2.31±0.02%ID/g,高于对照组。
  • 离体生物分布BXPC-3肿瘤摄取为1.90±0.59%ID/g,高于其他。

临床怎么用

  • 作者认为[68Ga]Ga-NOTA-PFCM01提供了无创评估c-Met表达的方法。
  • 作者认为[68Ga]Ga-NOTA-PFCM01具有作为未来临床应用的前瞻性PET显像剂的潜在作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent form of pancreatic cancer, with high malignancy and poor prognosis. The cellular mesenchymal-epithelial transition factor (c-Met) is overexpressed in 84% of PDAC and plays a critical role in tumor progression, which is closely associated with poor patient outcomes. In this study, a new 68Ga-labeled nanobody ([68Ga]Ga-NOTA-PFCM01) was developed for the visualization of c-Met in PDAC models. METHODS: The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) data were utilized to assess MET expression and overall survival in patients with different cancers. By immunizing an alpaca with recombinant human c-Met, three clones of nanobodies were screened, and the binding affinity was tested by bio-layer interferometry (BLI). The binding epitope of the nanobodies and c-Met was predicted by AlphaFold3. c-Met expression in human PDAC cell lines was evaluated using western blot, flow cytometry, and confocal microscopy. NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) chelator was used to label the nanobodies with 68Ga. PET imaging, semiquantitative uptake, and biodistribution research were carried out in tumor xenografts. Histological staining was performed on tumor tissues to characterize the expression of c-Met. In addition, PET imaging in non-human primates was performed to assess pharmacokinetics and biodistribution of the nanobody. RESULTS: Based on TCGA and GTEx data, MET expression in pancreatic adenocarcinoma (PAAD) is significantly higher than that in normal tissues (P < 0.001). Patients with high MET expression have lower overall survival rates than those with low MET expression. c-Met expression was the highest in BXPC-3 cells but the lowest in MIA PaCa-2 cells, which were set as the positive and negative models respectively. PFCM01 was screened and selected with an excellent binding property with the KD value of 0.16 nM. The radiochemical purity (RCP) of [68Ga]Ga-NOTA-PFCM01 was high, with good in vivo and in vitro stability. Semiquantitative analysis of small animal positron emission tomography/computed tomography (PET/CT) imaging demonstrated significantly higher tumor uptake in BXPC-3 tumors at 2 h post-injection (2.31 ± 0.02%ID/g) than control groups. Ex vivo biodistribution also showed a high uptake of BXPC-3 tumors (1.90 ± 0.59%ID/g) than others, which was further verified the PET imaging results. Histological staining showed high expression of c-Met in BXPC-3 but low in MIA PaCa-2 tumor tissues. In healthy cynomolgus monkeys, PET imaging revealed rapid renal excretion of [68Ga]Ga-NOTA-PFCM01. No significant radioactive uptake was observed in the liver, stomach, intestines, pancreas, or muscles, indicating its favorable pharmacokinetics and translational potential. CONCLUSIONS: [68Ga]Ga-NOTA-PFCM01 showed a specific and high tumor uptake in c-Met-positive PDAC models, providing a noninvasive method to assess c-Met expression. Besides, it demonstrated good pharmacokinetic characteristics in non-human primates. Therefore, [68Ga]Ga-NOTA-PFCM01 provided the potential role as a prospective PET imaging agent for future clinical applications.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Sun X, Yang Q, Song L, et al. ImmunoPET imaging of c-Met using a nanobody-based tracer [68Ga]Ga-NOTA-PFCM01 in pancreatic ductal adenocarcinoma models and non-human primates. Eur J Nucl Med Mol Imaging. 2025. PMID: 40632219. doi:10.1007/s00259-025-07441-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。